Preclinical Characterization of LY3209590, a Novel Weekly Basal Insulin Fc-Fusion Protein

The benefit of once-weekly basal insulin is less frequent dosing, which has the potential to reduce the barrier to injection therapy and impact patient activation, adherence and compliance, quality of life, and outcomes. Basal Insulin Fc (BIF, LY3209590, or insulin efsitora alfa) is a once-weekly basal insulin in clinical testing for type 1 and type 2 diabetes mellitus. BIF is comprised of a novel single-chain variant of insulin fused to a human IgG2 fragment crystallizable region of an antibody domain using a peptide linker. The in vitro binding affinity of BIF for the human insulin receptor (IR) was two orders of magnitude weaker rela-tive to human insulin. BIF stimulated IR phosphorylation in cells with reduced potency, yet full agonism, and exhibited a signifi-cantly faster dephosphorylation kinetic profile than human insu-lin or AspB10 insulin. BIF stimulated de novo lipogenesis in 3T3-L1 adipocytes and cell proliferation in SAOS-2 and H4IIE cells with $70-fold reduction in in vitro potency compared with human insulin. BIF possessed markedly reduced binding to hIGF-1R, making definitive measurements unattainable. In vivo pharmacology studies using streptozotocin-treated diabetic rats demonstrated a significant decrease in blood glucose compared with vehicle-treated animals 24 hours post-injection, persisting through 336 hours following subcutaneous adminis-tration. In streptozotocin-treated rats, BIF reached time at max-imum concentration at 48 hours and possessed a clearance rate of-0.85 ml/h per kg, with a terminal half-life of-120 hours following subcutaneous administration. These results demon-strate BIF has an in vitro pharmacological profile similar to na-tive insulin, with significantly reduced potency and an extended time-action profile in vivo that supports once-weekly dosing in humans.SIGNIFICANCE STATEMENT BIF is a novel basal insulin Fc-fusion protein designed for once -weekly dosing. In this study, we demonstrate that BIF has an in vitro pharmacological profile similar to human insulin, but with weaker potency across assays for IR binding and activity. BIF has a PD and PK profile in STZ-treated rats supportive of weekly dosing in humans.